Table of Contents
USE OF PROCEEDS
We estimate that the net proceeds from this offering will be approximately $375.5 million (or $431.9 million if the underwriters
exercise in full their option to purchase 588,240 additional shares), after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.
of September 30, 2017, we had cash and cash equivalents of $374.2 million. We intend to use the net proceeds from this offering, together with our existing cash and
cash equivalents, as follows:
- approximately $225 million to $270 million to fund our research, manufacturing and clinical activities to support our programs in
SMA, including our recently announced trial in pre-symptomatic patients with SMA Types 1, 2 and 3 and our pediatric "all comers" trial in patients with SMA Types 1, 2 and 3, and related
regulatory activities, as well as our programs in Rett syndrome and ALS;
- approximately $140 million to $175 million to fund pre-commercial activities including medical affairs, development of commercial
initiatives for the potential launch of AVXS-101 and licensing activities; and
- the balance for other general corporate purposes, including general and administrative expenses and working capital.
expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus supplement,
we cannot predict with complete certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the actual amounts that we will spend on the uses set
forth above. We believe opportunities may exist from time to time to expand our current business through the acquisition or in-license of complementary product candidates. While we have no current
agreements for any specific acquisitions or in-licenses at this time, we may use a portion of the net proceeds for these purposes.
amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials, the timing of regulatory submissions, the uncertainties
associated with regulatory review process, and other development and commercialization efforts for AVXS-101 and our other product candidates, as well as the amount of cash used in our operations. We
therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes described above. We may find it necessary or advisable to use the net proceeds for other purposes, and
we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term,
interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.